Apricus Biosciences, Inc. 14.03.2012 15:05 --------------------------------------------------------------------------- SAN DIEGO, 2012-03-14 15:05 CET (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI) (http://www.apricusbio.com), San Diego Hospice (the 'Hospice') and The Institute for Palliative Medicine today announced the signing of a clinical development collaboration to study the use of the Company's NexACT(r) Technology in the hospice setting. Clinicians at the Hospice will be evaluating the topical delivery of common hospice medications to determine if the use of such products with the Company's NexACT(r) drug delivery technology can have greater efficacy in delivering certain drugs to Hospice patients. Apricus Bio's NexACT(r) technology consists of a small molecule permeation enhancer called Dodecyl 2-(N,N dimethylamino)-propionate (DDAIP), which enables the rapid absorption of high concentrations of an active pharmaceutical ingredient directly at the target site. The Company believes that drugs that are combined to DDAIP can thus better penetrate the skin and be delivered to a patient's bloodstream or where they are needed. The first compound the Hospice will evaluate is chlorpromazine, commonly prescribed to control nausea and vomiting. In human skin permeation studies conducted by the Company, twice as much chlorpromazine was delivered through the skin when used with NexACT(r), as compared to the currently-used topical formulation of chlorpromazine. The current formulation of chlorpromazine used by the Hospice combines the drug with Pluronic Lecithin Organogel ('PLO'), a mixture of oil and water that thickens to form a gel to enhance penetration through the skin. Dr. Bassam Damaj, Apricus Bio's Chairman, President and CEO commented, 'Our NexACT(r) drug delivery technology is ideally suited to deliver therapeutic compounds in the hospice setting where non-invasive delivery technologies complement the Hospice's mission 'to prevent and relieve suffering and promote quality of life, at every stage of life.' Our studies also indicate that the NexACT(r) technology works better than the current topical alternatives.' Charles F. von Gunten, MD, PhD, Editor-in-Chief, Journal of Palliative Medicine and Provost, The Institute for Palliative Medicine at the San Diego Hospice also commented, 'Alternative clinically proven and validated drug delivery technologies such as Apricus Bio's NexACT(r) are badly needed in the hospice patient setting where many patients can't or won't tolerate more invasive delivery methods such as injections. We are thrilled to begin this collaboration.' About Apricus Biosciences, Inc. Apricus Bio is a San Diego-based revenue-generating hybrid specialty pharmaceutical company, with commercial products and a broad pipeline across numerous therapeutic classes. Revenues and growth are driven from the sales of the Company's commercial products through its Apricus Pharmaceuticals USA, Inc. and NexMed (USA), Inc. subsidiaries and through out-licensing in certain territories of its product pipeline and NexACT(r) technology. Apricus Bio currently markets Totect(r) (dexrazoxane HCl), the only drug approved in the US for the treatment of anthracycline extravasation. The Company also plans to market in the U.S. or certain other countries the following products: (a) Granisol(r) (granisetron HCI) oral solution, the only FDA-approved, oral, ready-to-use liquid solution of granisetron, (b) Aquoral(tm), an FDA-cleared, prescription-only spray for the treatment of Xerostomia (the medical term for dry mouth due to a lack of saliva) and (c) NitroMist(r) (nitroglycerin sublingual spray), an FDA-approved nitrate vasodilator indicated for acute relief of an attack or acute prophylaxis of angina pectoris (chest pain) due to coronary artery disease (narrowing of the blood vessels that supply blood to the heart). Apricus Bio's current NexACT(r) pipeline includes Vitaros(r), approved in Canada for the treatment of erectile dysfunction, as well as compounds in development from pre-clinical through pre-registration currently focused on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes and Consumer Healthcare. The Company also expects to develop and/or acquire and then bring to market additional pharmaceutical products in areas of care that will benefit patient needs worldwide. For further information on Apricus Bio, visit http://www.apricusbio.com, and for information on its subsidiary please visit http://www.nexmedusa.com. You can also receive information at http://twitter.com/apricusbio. About San Diego Hospice and The Institute for Palliative Medicine San Diego Hospice and The Institute for Palliative Medicine was the first non-profit hospice program in San Diego County, since 1977, and one of the largest community-owned, non-profit hospices in the country, bringing compassionate, expert medical care to more than 1,000 seriously ill adults and children each day throughout San Diego County. In addition to patient care, The Institute for Palliative Medicine at San Diego Hospice is internationally recognized for its innovative education programs, patient/family-centered research and evidence-based advocacy since 1989. The Institute for Palliative Medicine trains more than 4,000 healthcare professionals each year in the advances in hospice and palliative care. For more information, visit www.sdhospice.org, or visit their online communities: www.Facebook.com/SanDiegoHospice or , www.Twitter.com/SanDiegoHospice, or www.YouTube.com/SanDiegoHospice, or call toll-free 866-688-1600. Apricus Bio's Forward-Looking Statement Safe Harbor Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, its ability to further develop its products and product candidates, to have its products and product candidates approved by relevant regulatory authorities, to successfully commercialize such products as Totect(r), Granisol(r), Aquoral(tm) and NitroMist(tm) and Vitaros(r) for erectile dysfunction and NexACT(r) product candidates and drug delivery technology such as that to be used by the San Diego Hospice and to achieve its development, commercialization and financial goals. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company. CONTACT: Apricus Bio Investor Relations: David Pitts Argot Partners 212-600-1902 david@argotpartners.com News Source: NASDAQ OMX 14.03.2012 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Apricus Biosciences, Inc. United States Phone: Fax: E-mail: Internet: ISIN: US9901429525 WKN: End of Announcement DGAP News-Service ---------------------------------------------------------------------------
DGAP-News: Apricus Biosciences, San Diego Hospice and The Institute for Palliative Medicine Announce a Broad Clinical Research Program Using NexACT(R) Technology
| Source: EQS Group AG